* Says Read rewarded for efforts to redefine Pfizer
* Cites $1 bln in cost cuts, new drugs, share buybacks
By Ransdell Pierson
March 15 Pfizer Inc said Chief
Executive Ian Read's compensation jumped more than 40 percent
last year to $25 million as he steered a steady course for the
world's biggest drugmaker while its Lipitor cholesterol fighter
began facing competition from cheaper generics.
Read was named CEO in December, 2010, after the surprise
resignation of Jeffrey Kindler, and three months ago he assumed
additional responsibility as chairman of the New York-based
company. Before taking the helm of Pfizer, he held numerous
senior executive roles there for 32 years, including as the
global head of pharmaceuticals.
His basic salary for 2011 rose to $1.7 million, from $1.2
million in 2010, the company said on Thursday in a regulatory
filing. The value of his stock awards more than doubled to $5.7
million, while the value of his stock option awards rose almost
six-fold to $5.7 million, according to the filing.
Read's annual cash incentive awards more than doubled to
$3.5 million, while all other compensation rose to $319,288. The
value of his pension and non-qualified deferred compensation
rose $6.89 million, compared with almost $11 million in 2010,
when Read's years of service at Pfizer reached a target
"Under the leadership of Ian Read, we set a course to
redefine and strengthen Pfizer," the filing said, as the company
faced pricing pressures on its many medicines and the loss of
U.S. marketing exclusivity in November on Lipitor. The world's
longtime best-selling drug had annual global sales of $13
billion at its peak.
Pfizer said it had improved its performance during 2011 by
reducing research spending by nearly $1 billion. That feat came,
however, at the expense of thousands of Pfizer researchers,
whose jobs are being eliminated along with numerous laboratories
in an effort to ultimately slash Pfizer research spending by up
to $2 billion a year.
Moreover, the drugmaker said it returned $15.2 billion to
shareholders through dividends and stock buybacks last year and
sought approvals for a number of new drugs.
The company, which bought U.S. rival Wyeth for $67 billion
in late 2009 to bolster its array of medicines, has developed
few big-selling drugs of its own since impotence-treatment
Viagra was introduced in 1998.
Pfizer, under Read, has narrowed its focus to five main
therapeutic areas and is considering either selling or spinning
off its nutritional products and animal health units.
Proceeds from the transactions will likely be used to buy
back company shares, Read has said, delighting investors and
helping boost company shares almost 27 percent in the past
Rival drugmaker Johnson & Johnson said on Wednesday
its retiring Chief Executive William Weldon, 63, received $26.8
million in total compensation last year, down from $28.7 million
But the company said Weldon, who has accepted personal blame
for costly recalls of scores of its over-the-prescription drugs
over the past three years, could receive more than $140 million
when he retires as CEO next month.
J&J in a regulatory filing said Weldon had accumulated $95.1
million in various compensation programs and $48.4 million in
pension benefits during his decade as CEO and 40 years with the
diversified healthcare company.